

# Time to Insulin Initiation Cannot Be Used in Defining Latent Autoimmune Diabetes in Adults

SINEAD BROPHY, PHD<sup>1</sup>  
 KNUD YDERSTRÆDE, PHD<sup>2</sup>  
 DIDAC MAURICIO, PHD<sup>3</sup>  
 STEPHEN HUNTER, PHD<sup>4</sup>  
 MOHAMMED HAWA, PHD<sup>5</sup>  
 PAOLO POZZILLI, PHD<sup>6</sup>  
 GUNTRAM SCHERTHNER, PHD<sup>7</sup>

NANETTE SCHOOT, PHD<sup>8</sup>  
 RAFFAELLA BUZZETTI, PHD<sup>9</sup>  
 HELEN DAVIES, PHD<sup>1</sup>  
 DAVID LESLIE, PHD<sup>5</sup>  
 RHYS WILLIAMS, PHD<sup>1</sup>  
 ON BEHALF OF THE ACTION LADA GROUP\*

**OBJECTIVE** — Latent autoimmune diabetes in adults is type 1 diabetes presenting as non-insulin dependent diabetes. One feature of the selection criteria is time independent of insulin treatment. We examine the validity of this criterion.

**RESEARCH DESIGN AND METHODS** — Patients were recruited in nine European centers, and clinicians reported on criteria for initiating insulin. All patients were tested for GAD antibodies (GADAs) in a central laboratory. We examined time to insulin treatment for GADA-positive patients in six participating centers.

**RESULTS** — There was intercenter variation in the criteria used to initiate insulin. Median time to insulin was 16.15 months (interquartile range 6.7–25.5) in centers with GADA testing compared with 45.6 months (29.5–61.8) in centers without routine GADA testing ( $P < 0.002$ ).

**CONCLUSION** — Time to insulin should not be used to define patients with LADA because it is dependent on local clinical judgment and the use of laboratory tests for GADA.

*Diabetes Care* 31:439–441, 2008

Latent autoimmune diabetes in adults (LADA) is a term applied to patients with apparent type 2 diabetes but who have pancreatic islet cell auto-antibodies. LADA patients have features of type 1 diabetes, including genetic risk markers and reduced rates of the metabolic syndrome (1–3). However, the selection criteria used in LADA research varies greatly (4–13). While time from diagnosis to insulin treatment is not included in some definitions, others require

freedom from insulin treatment for a variable period ranging from 3 to 12 months. In this study, we examine the validity of using time to insulin treatment as part of a definition of LADA.

## RESEARCH DESIGN AND METHODS

Nine centers recruited patients (aged 30–69 with primary diabetes, diagnosed within the past 5 years). GAD antibody (GADA) tests were performed in St. Bartholomew's Hospital and

in the London Hospital using a Diabetes Antibody Standardization Programme (DASP) validated assay (in the 2005 DASP antibody workshop, the assay had a sensitivity 72% and specificity 95%). Values  $>70$  World Health Organization units were regarded as positive. All patients were assayed in duplicate and included an in-house positive and negative control subject.

Clinicians in all nine centers completed a questionnaire reporting the criteria for initiating insulin in their center. One questionnaire per center reported the consensus opinion of the clinicians in that center. Center size varied between two and seven clinicians. The medical notes of the GAD-positive patients (522 of 5,812) were analyzed to examine time to insulin. Three centers were excluded from the analysis because these data were not in a format that could be analyzed. Cox regression/Kaplan-Meier analysis were used to examine survival in terms of time to insulin in GAD-positive patients in centers performing routine GADA testing compared with those not testing for GADA.

**RESULTS** — The criteria for initiating insulin varied between centers. All used A1C and weight loss, eight of nine considered ketones, seven of nine considered complications, six of nine considered patient preference and/or other treatments, and five of nine used age and/or C-peptide. All the centers except two in the U.K. used GADA testing.

In centers where GADA testing was performed, the median time to insulin treatment for those testing GADA positive in the central laboratory was earlier compared with that for centers with no GAD testing (Fig. 1). For GAD testing centers (Odense,  $n = 32$ ; Barcelona,  $n = 67$ ; Vienna,  $n = 35$ ; and Lyon,  $n = 68$ ), the median time was 4.8 (interquartile range 0–12.8), 9.4 (1.1–17.8), 31 (3.5–59), and 29.4 (17.6–41) months, respectively, compared with that of non-GADA testing areas (Belfast,  $n = 66$ ; London,  $n = 50$ ) where median time (months) to insulin treatment was 38.1 (20.5–55.6) and 47 (29.5–64.8) months ( $P <$

From the <sup>1</sup>School of Medicine, Swansea University, Swansea, U.K.; the <sup>2</sup>Department of Endocrinology, University Hospital of Odense, Odense, Denmark; the <sup>3</sup>Department of Endocrinology and Nutrition, Hospital de Sant Pau, Barcelona, Spain; the <sup>4</sup>Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, U.K.; the <sup>5</sup>Department of Diabetes and Molecular Medicine, St. Bartholomew's Hospital, London, U.K.; the <sup>6</sup>Department of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy; the <sup>7</sup>Department of Medicine, Rudolfstiftung Hospital, Vienna, Austria; the <sup>8</sup>German Diabetes Centre, University of Duesseldorf, Duesseldorf, Germany; and <sup>9</sup>Dipartimento Scienze Cliniche, University of Rome, Sapienza, Italy.

Address correspondence and reprint requests to Dr. Sinead Brophy, School of Medicine, Swansea University, Swansea SA2 8PP, U.K. E-mail: s.brophy@swansea.ac.uk.

Received for publication 9 July 2007 and accepted in revised form 10 December 2007.


Published ahead of print at <http://care.diabetesjournals.org> on 14 December 2007. DOI: 10.2337/dc07-1308.

\*A full list of the members of the Action LADA Group can be found in an online appendix at <http://dx.doi.org/10.2337/dc07-1308>.

**Abbreviations:** GADA, GAD antibody; LADA, latent autoimmune diabetes.

© 2008 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.



**Figure 1**—Time to insulin for LADA patients (as identified by the central laboratory) in centers with GAD testing (solid line;  $n = 218$ ) compared with that in centers without GAD testing (dotted line,  $n = 116$ ) (hazard ratio 0.587 [95% CI 0.4–0.8],  $P = 0.02$ ).

0.0001). Therefore, if a definition of LADA stated that a person should be independent of insulin for 6 months (1,7,11), estimates of prevalence would be low in Denmark, Austria, France, and Spain but high in Belfast and London.

**CONCLUSIONS**— Time to insulin treatment is dependent on local clinical judgement and not on the disease process. Since that judgement is based on the presence of GADA, it follows that to define LADA on GADA positivity and the lack of initial need for insulin treatment is fraught with difficulties since the one often precludes the other.

The term latent, when applied to LADA, refers to the latency of autoimmunity, which is only revealed by testing for autoantibodies. The widespread clinical use of GADA testing on the continent but not in the U.K. means that the presence of a diabetes-associated autoantibody is no longer latent in many European centers. The level of GADA titer influences progression to insulin therapy. In the UK Prospective Diabetes Study 71 (14), the risk of requiring insulin in patients with GADA levels of 20–37.4 units was 20%, but GADA levels of 37.5–101 units give a 50–75% risk. These findings are supported by Buzzetti et al. (15), who found

a bimodal distribution of GADA titers. It is important to note that there is large variation between laboratories with respect to GADA levels defining an abnormality, and caution should be exercised in using defined units; for our study, a cutoff of 70 World Health Organization units was used. Therefore, to accurately identify patients with LADA, perhaps a minimum level of GAD units should be selected within a definition (16).

Another feature of LADA not considered here is the presence of ketonuria. Ketonuria is a feature of classical type 1 diabetes but can also occur in type 2 diabetes. Some patients, from certain ethnic groups, can present with ketoacidosis but subsequently come off insulin treatment, and some may have GADA. In LADA patients, neither ketonuria nor ketoacidosis is present at diagnosis, and in this way LADA is distinct from ketosis prone diabetes, though the distinction may in some cases be more apparent than real (17). To separate LADA from classical type 1 diabetes, we may need to use some defined level of ketonuria or ketonaemia at diagnosis.

A further criteria used in the diagnosis of LADA is age. However, patients with GADA can present with non-insulin requiring diabetes in childhood (17,18). In

our opinion, criteria to define LADA could include the presence of diabetes-associated autoantibodies, without ketoacidosis at diagnosis and irrespective of time independent of insulin treatment.

**Acknowledgments**— The projected was funded by the 5th Framework Programme of EU and DeveloGen. D. Mauricio was supported by a grant from Instituto Carlos III, Spain (Project FIS 061104)

## References

1. Furlanos S, Perry C, MS Stein, Stankovich J, Harrison LC, Colman PG: A clinical screening tool identifies autoimmune diabetes in adults. *Diabetes Care* 29: 970–975, 2006
2. Leslie RD, Williams R, Pozzilli P: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. *J Clin Endocrinol Metab* 91: 1654–1659, 2006
3. Rosario PW, Reis JS, Fagundes TA, Calsolari MR, Amim R, Silva SC, Purisch S: Latent autoimmune diabetes in adults (LADA): usefulness of anti-GAD antibody titers and benefit of early insulinization. *Ar Qbras Endocrinol Metabol* 51:52–58, 2007
4. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, Harris RA, Robertson JA, Lernmark A: Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. *J Diabetes Complications* 19:238–246, 2005
5. Cabrera-Rode E, Diaz-Horta PP, Tiberti C, Molina G, Arranz C, Martin J, Licea M, De Leiva A, Puig-Domingo M, Dimario U: Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment. *Autoimmunity* 35:469–474, 2002
6. Kobayashi T, Nakanishi K, Murase T, Kosaka K: Small doses of subcutaneous insulin as a strategy for preventing slowly progressive  $\beta$ -cell failure in islet cell antibody-positive patients with clinical features of NIDDM. *Diabetes* 45:622–626, 1996
7. Maruyama T, Shimada A, Kanatsuka A, Kasuga A, Takei I, Yokoyama J, Kobayashi T: Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. *Ann N Y Acad Sci* 1005:362–369, 2003
8. Zhou Z, Li X, Huang G, Peng J, Yang L, Yan X, Wang J: Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). *Diabete Metab Res Rev* 21: 203–208, 2005
9. Zhu LQ, Liu YH, Huang M, Wei H, Liu Z: [Study on improvement of islet beta cell

- function in patients with latent autoimmune diabetes mellitus in adults by integrative Chinese and Western medicine]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 24:581–584, 2004 [article in Chinese]
10. Rosario PW, Reis JS, Amim R, Fagundes TA, Calsolari MR, Silva SC, Purisch S: Comparison of clinical and laboratory characteristics between adult-onset type 1 diabetes and latent autoimmune diabetes in adults. *Diabetes Care* 28:1803–1804, 2005
  11. Vatay A, Rajczy K, Pozsonyi E, Hosszulfalusi N, Prohaszka Z, Fust G, Karadi I, Szalai C, Grosz A, Bartfai Z, Panczel P: Differences in the genetic background of latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus. *Immunol Lett* 84:109–115, 2002
  12. Isomaa B, Almgren P, Henricsson M, Taskinen MR, Tuomi T, Groop L, Sarelin L: Chronic complications in patients with slowly progressing autoimmune type 1 diabetes (LADA). *Diabetes Care* 22:1347–1353, 1999
  13. Yang L, Zhou SG, Huang G, Ouyang LL, Li X, Yan X: Six-year follow-up of pancreatic beta cell function in adults with latent autoimmune diabetes. *World J Gastroenterol* 11:2900–2905, 2005
  14. Davis TM, Wright AD, Mehta ZM, Cull CA, Stratton IM, Bottazzo GF, Bosi E, Mackay IR, Holman RR: Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). *Diabetologia* 48:695–702, 2005
  15. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Do4tta F, Bosi E, the Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study Group: High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. *Diabetes Care* 30:932–938, 2007
  16. Kondrashova A, Viskari H, Kulmala P, Romanov A, Ilonen J, Hyoty H, Knip M: Signs of  $\beta$ -cell autoimmunity in nondiabetic schoolchildren: a comparison between Russian Karelia with a low incidence of type 1 diabetes and Finland with a high incidence rate. *Diabetes Care* 30:95–100, 2007
  17. Aycan Z, Berberoglu M, Adiyaman P, Ergur AT, Ensari A, Evliyaoglu O, Siklar Z, Ocal G: Latent autoimmune diabetes mellitus in children (LADC) with autoimmune thyroiditis and Celiac disease. *J Pediatr Endocrinol Metab* 17:1565–1569, 2004
  18. Reinehr T, Schober E, Wiegand S, Thon A, Holl R: Beta-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? *Arch Dis Child* 91:473–477, 2006